Company / SG&A per Share
Neurocrine Biosciences SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$11.63
FY2025
5-year range
$6.24 / $11.63
FY2021-FY2025
Trend
+14.0%
vs FY2024
Sector context
#13 of 208
Health Care
What the data says
Among 208 Health Care companies, Neurocrine Biosciences is in the bottom 6% for sg&a per share. SG&A per Share has increased for 9 consecutive years, from $0.79 in FY2016 to $11.63 in FY2025.
Based on SEC 10-K filings.
11.63 in FY2025 with a 5-year CAGR of +19.9%. Top quartile in the Health Care sector.
Increased from $9.20 to $11.63 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +13.6%
- 5-Year CAGR
- +19.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 208This company $11.63 Sector average $29.78
▼
-60.9% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's sg&a per share has grown for 9 consecutive years.
- In FY2025, sg&a per share increased 14.0% year-over-year.
- Ranks #13 out of 208 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.63 | +14.0% |
| FY2024 | $10.20 | +10.9% |
| FY2023 | $9.20 | +16.0% |
| FY2022 | $7.93 | +27.1% |
| FY2021 | $6.24 | +32.9% |
| FY2020 | $4.69 | +20.4% |
| FY2019 | $3.90 | +39.1% |
| FY2018 | $2.80 | +43.3% |
| FY2017 | $1.96 | +147.8% |
| FY2016 | $0.79 | +85.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026